E Fund Management Co., Ltd. Macrogenics Inc Transaction History

E Fund Management Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$9.77 - $21.47 $162,836 - $357,840	16,667 New	16,667 $245,000
Q2 2022 Aug 15, 2022	SELL	$2.25 - $9.99 $23,438 - $104,065	-10,417 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$8.12 - $16.9 $47,290 - $98,425	5,824 Added 126.8%	10,417 $92,000
Q1 2021 May 12, 2021	BUY	$18.99 - $33.2 $87,221 - $152,487	4,593 New	4,593 $146,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.